

November 25, 2022

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Growth Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

The final results of SP-05 arfolitixorin Phase III study

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner today announced that analysis of the SP-05 arfolitixorin Phase III study's final data confirmed topline results presented on August 3, 2022.

For more information, please refer to the Isofol's website.

<https://isofolmedical.com/>

###